EMERYVILLE, Calif., April 08, 2019 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug…Original Article
Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for Fintepla New Drug Application
